Cellular Biomedicine Group (CBMG) Misses Q2 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts CBMG Hot Sheet
Join SI Premium – FREE
Cellular Biomedicine Group (NASDAQ: CBMG) reported Q2 EPS of ($0.44), $0.07 worse than the analyst estimate of ($0.37). Revenue for the quarter came in at $657 thousand versus the consensus estimate of $650 thousand.
For earnings history and earnings-related data on Cellular Biomedicine Group (CBMG) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SPS Commerce (SPSC) Tops Q3 EPS by 16c; Offers Guidance
- Exponent, Inc. (EXPO) Tops Q3 EPS by 4c; offers outlook
- AptarGroup (ATR) Tops Q3 EPS by 5c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
